Barbara S. Fox, PhD (CEO)
Dr. Fox is the founding CEO of Tilos Therapeutics. She has previously served as Entrepreneur-in-Residence at Partners Innovation Fund, founder and CEO of Avaxia Biologics, founder and CSO of Recovery Pharmaceuticals, VP Discovery and Immunology at ImmuLogic Pharmaceutical Corp., and Associate Professor of Rheumatology at the U. Maryland School of Medicine. Dr. Fox received her AB in chemistry from Bryn Mawr, her PhD in chemistry from MIT and trained as a post-doc in cellular immunology at the NIH. She was an EY Entrepreneur of The Year™ 2014 Award finalist in New England.
John Edwards (Executive Chair)
John Edwards has over 30 years of experience in discovery, development, and global commercialization of biopharmaceuticals, involving over 10 FDA approved biologics at a series of successful biotechnology companies. Most recently he helped lead Adnexus from a start-up to the $450M acquisition by BMS within 4 years, where he then continued with the company for next 3 years serving as President. Earlier, Mr. Edwards was VP Sales, Marketing, and Medical Affairs at Transkaryotic Therapies and had a 15-year tenure with Genetics Institute/Wyeth, where he held senior-level positions in R&D, manufacturing, and commercial operations. Currently, Mr. Edwards also serves as executive chairman of F-star. He started his career in R&D at Genzyme (pre-IPO). Mr. Edwards received his M.B.A. from Boston University and his B.S. in Chemical Engineering from the U. Massachusetts at Amherst.